April 2, 2026
The bioprocessing CDMO model is broken. Innovation in continuous manufacturing is the only way to survive Asian competition and big pharma shifts.
March 31, 2026
CEO Juergen Mairhofer on overcoming E. coli's genetic instability for 40-day continuous manufacturing by decoupling growth and production.
March 26, 2026
High-throughput screening isn't a simple 'black box.' It's a complex tool requiring deep expertise to avoid costly scale-up mistakes.
March 24, 2026
Avoid costly scale-up failures by optimizing early bioprocess screening. This episode compares high-throughput systems vs. traditional methods.
March 19, 2026
Molecular farming uses plants for rapid biopharma production, offering a low-cost, scalable alternative to traditional CHO and microbial systems.
March 17, 2026
Professor Waranyoo Phoolcharoen explains molecular farming, a method using plants as biofactories to produce biopharma in weeks, not months.
March 12, 2026
De-risk bioprocess automation by prioritizing upfront validation and a 'Minimum Testable Product' to find fatal flaws before costly engineering.
March 10, 2026
Most bioprocess automation projects fail from poor problem definition, not technology. Success lies in understanding the process first.
March 5, 2026
Master Biologics CMC from IND to BLA using the house analogy. Solid foundations and robust process validation determine regulatory success.
March 3, 2026
Biologics development is like building a house. Your Phase 1 CMC decisions form an irreparable foundation for regulatory success. Get it right.
February 26, 2026
Deep Blue Biotech's strategy for scaling cyanobacteria production: partner with CMOs, build a pilot plant, then license for mass-market reach.
February 24, 2026
CEO Tim Corcoran reveals how cyanobacteria enable carbon-neutral biomanufacturing at lower costs than fermentation for high-value chemicals.
February 17, 2026
Master glycan engineering with raffinose. This guide provides an 8-week, 3-experiment protocol to increase high mannose for biosimilar matching.
February 10, 2026
Raffinose in media increases high-mannose glycans 2.8x, solving biosimilar glycan mismatch without cell re-engineering or inhibitors.
February 5, 2026
Radiopharmaceuticals are entering a new era, driven by theragnostics, advanced preclinical models (PDX), and strategic CRO partnerships.
February 3, 2026
Mastering radiopharmaceutical development requires precise preclinical models to overcome unique challenges in this rapidly growing oncology field.
January 29, 2026
Cellular agriculture is more than lab meat. Explore scaling cacao & coffee to meet global food demand, focusing on simpler, safer products.
January 27, 2026
Steven Lang of California Cultured explains how producing cacao from plant cells offers a cost-effective, scalable vision for cellular agriculture.
January 22, 2026
Advanced 3D cell models reveal therapeutic resistance missed by 2D cultures, offering a more predictive preclinical research platform.
January 20, 2026
Catarina Brito explains why bioprocess must be biology-first, pioneering advanced 3D cell models to replace traditional preclinical methods.
January 15, 2026
From 10k structures to 1.8B interactions, A-alpha Bio's platform breaks the data bottleneck, fueling AI to engineer complex therapeutics.
January 13, 2026
A-AlphaBio's Troy Lionberger explains how measuring millions of protein interactions and using AI transforms antibody discovery from years to months.
January 8, 2026
Silkworm pupae are being repurposed as living bioreactors to produce complex vaccines and proteins, offering a fast, scalable, and low-cost platform.
January 6, 2026
Kaiko pioneers silkworm biomanufacturing, turning these ancient creatures into powerful, consistent bioreactors for vaccines and complex proteins.
December 18, 2025
AI is transforming biomanufacturing from data silos to smart factories. Start small with clean data and leverage cloud computing for scale.
December 16, 2025
AI is shifting bioprocessing from an experimental to a computational science. Digital twins and ML are slashing timelines & de-risking scale-up.
